Monoaminergic and Kynurenergic Characterization of Frontotemporal Dementia and Amyotrophic Lateral Sclerosis in Cerebrospinal Fluid and Serum by Janssens, Jana et al.
 
 
 University of Groningen
Monoaminergic and Kynurenergic Characterization of Frontotemporal Dementia and
Amyotrophic Lateral Sclerosis in Cerebrospinal Fluid and Serum
Janssens, Jana; Vermeiren, Yannick; van Faassen, Martijn; van der Ley, Claude; Kema, Ido





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2020
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Janssens, J., Vermeiren, Y., van Faassen, M., van der Ley, C., Kema, I. P., & De Deyn, P. P. (2020).
Monoaminergic and Kynurenergic Characterization of Frontotemporal Dementia and Amyotrophic Lateral
Sclerosis in Cerebrospinal Fluid and Serum. NEUROCHEMICAL RESEARCH, 45(5), 1191-1201.
https://doi.org/10.1007/s11064-020-03002-5
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the






Monoaminergic and Kynurenergic Characterization of Frontotemporal 
Dementia and Amyotrophic Lateral Sclerosis in Cerebrospinal Fluid 
and Serum
Jana Janssens1,2 · Yannick Vermeiren1,2 · Martijn van Faassen3 · Claude van der Ley3 · Ido P. Kema3 · 
Peter P. De Deyn1,2,4
Received: 31 October 2019 / Revised: 30 December 2019 / Accepted: 26 February 2020 
© The Author(s) 2020
Abstract
Exploring the neurochemical continuum between frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) 
with respect to monoamines and kynurenines in cerebrospinal fluid (CSF) and serum, may be useful to identify possible new 
research/therapeutic targets. Hence, we analysed monoamines and kynurenines in CSF and serum derived from patients with 
FTD (n = 39), ALS (n = 23), FTD-ALS (n = 4) and age-matched control subjects (n = 26), using reversed-phase ultra-high 
performance liquid chromatography (RP-UHPLC) with electrochemical detection (ECD) and liquid chromatography tandem 
mass spectrometry, respectively. We noted a shared dopaminergic disturbance in FTD and ALS when compared to CONTR, 
with significantly increased serum DA levels and decreased DOPAC concentrations, as well as decreased DOPAC/DA ratios 
in both disease groups. In CSF, significantly reduced DOPAC concentrations in FTD and ALS were observed as well. Here, 
a significant increase in DA levels and decrease in DOPAC/DA ratios was only found in FTD relative to CONTR. With 
respect to the kynurenine pathway (KP), we only found decreased HK/XA ratios, indicative for vitamin B6 status, in serum 
of ALS subjects compared to FTD. The dopaminergic commonalities observed in FTD and ALS might relate to a disturbance 
of dopaminergic nerve terminals in projection areas of the substantia nigra and/or ventral tegmental area, although these 
findings should first be confirmed in brain tissue. Lastly, based on the results of this work, the KP does not hold promise as 
a research/therapeutic target in FTD and ALS.
Keywords Biomarker · Neuropathology · Dementia · Neurophysiology
Introduction
Frontotemporal dementia (FTD) and amyotrophic lateral 
sclerosis (ALS) are devastating neurodegenerative disor-
ders demonstrating genetic and neuropathologic overlap. 
The most common shared genetic mutation is a GGG GCC 
expansion in C9ORF72, present in approximately 30–47% 
[1, 2] and 25–34% [1, 3] of familial ALS and FTD cases, 
respectively. This hexanucleotide expansion is most often 
associated with the presence of cytoplasmic inclusions 
containing transactive response DNA-binding protein of 
43 kDa (TDP-43) in both diseases [4, 5]. Consequently, 
these inclusions are found in up to 97% of ALS and 45% of 
FTD cases [6]. Next to the shared genetic and neuropatho-
logic characteristics, similarities in clinical presentation are 
also observed. Behavioural abnormalities and/or signs of 
cognitive impairment including executive dysfunction, are 
observed in 50% of patients with ALS, while 15% of these 
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s1106 4-020-03002 -5) contains 
supplementary material, which is available to authorized users.
 * Peter P. De Deyn 
 p.p.de.deyn@umcg.nl
1 Department of Biomedical Sciences, Neurochemistry 
and Behaviour, Institute Born-Bunge (IBB), University 
of Antwerp, Wilrijk, Antwerp, Belgium
2 Department of Neurology, Alzheimer Center 
Groningen, University Medical Center Groningen 
(UMCG) and University of Groningen, Hanzeplein 1, 
9713 GZ Groningen, The Netherlands
3 Department of Laboratory Medicine, University Medical 
Center Groningen (UMCG) and University of Groningen, 
Groningen, The Netherlands
4 Faculty of Medicine and Health Sciences, University 
of Antwerp, Wilrijk, Antwerp, Belgium
 Neurochemical Research
1 3
subjects reach the diagnostic criteria for FTD [7–10]. Like-
wise, similar frequencies of motor disturbances are observed 
in FTD [11, 12].
Although this clinicopathologic overlap has been well 
covered in the scientific literature, less is known about (mon-
oaminergic) neurotransmitter disturbances in ALS. As this 
condition is currently treated with strategies primarily tar-
geting glutamatergic neurotransmission and oxidative stress 
using riluzole and edaravone, respectively [13–15], offering 
limited benefit, other options based on alternative neuro-
transmitter systems could be explored. The relative success 
of selective serotonin reuptake inhibitors (SSRIs) in FTD 
might point to monoamines as interesting research targets 
in this disorder, and possibly also in ALS. Furthermore, as 
previous research demonstrated monoaminergic disturbance 
in brain tissue (reviewed in [16]) and cerebrospinal fluid 
(CSF) of FTD patients [17–19], investigating the occur-
rence of these substances in easily accessible body fluids 
such as blood, plasma or serum in ALS might be of interest 
to determine whether FTD and ALS also share neurochemi-
cal characteristics.
Due to its implication in (neuro-)inflammation, the 
kynurenine pathway (KP) has received increasing attention 
in immune-related diseases such as cancer [20, 21], HIV 
[22], and several neurodegenerative disorders including ALS 
[23–25]. Although few researchers have previously focused 
on determining the KP in samples derived from patients with 
ALS, it appears that concentrations of some neuroprotective 
and neurotoxic metabolites are altered in CSF and serum [23, 
26]. In FTD, however, little information regarding a possible 
dysregulation of this metabolic pathway can be found. Given 
the involvement of the KP in neuroinflammation and since 
this pathway is linked to the production of 5-HT via their 
common precursor l-tryptophan (TRP), not only 5-HT and 
other related monoamines, but also compounds of the KP 
could possibly represent an interesting means to investigate 
the neurochemical continuum of FTD-ALS.
Materials and Methods
Study Population
This retrospective study used CSF and serum samples 
derived from the NeuroBioBank of the Institute Born-Bunge 
(NBB-IBB (no. BB190113), Wilrijk). Monoamines and 
metabolites were analysed in CSF samples of patients suf-
fering from probable FTD (n = 39) [27], FTD-ALS (n = 4), 
suspected, possible and probable ALS (n = 23) [28], and 
age-matched control subjects (CONTR) (n = 26). Serum 
samples were derived from the same patients, although for 
3 ALS subjects, no serum samples were available. Patients 
and control subjects were recruited at the Memory Clinic 
of the Hospital Network Antwerp (ZNA) Middelheim and 
Hoge Beuken, as CSF and serum sampling was part of their 
clinical diagnostic workup. Psychiatric antecedents and cen-
tral nervous system pathology other than FTD and ALS were 
regarded as exclusion criteria. Control subjects came to the 
clinic because of (tension) headache, lumbar canal stenosis, 
cervicalgia/cervical myelopathy, carpal tunnel syndrome, 
nausea, chronic gait disorders, periodic fever syndrome, 
leucopenia, struma simplex, facial arteriovenous malfor-
mations, and sinusitis. In patients who gave brain donation 
consent, brain autopsy was generally performed within 6–8 h 
postmortem. The right hemisphere was immersion-fixated in 
a 12% formalin solution for neuropathological examination, 
while the left hemisphere was frozen at – 80 °C [29, 30]. In 
the FTD-ALS group, only one subject had neuropathological 
confirmation of the initial clinical diagnosis, with molecular 
lesions classified as TDP-43 Type B. Similarly, only one 
subject was neuropathologically confirmed as definite ALS. 
Genetically, 11 FTD subjects had a hexanucleotide expan-
sion in C9ORF72, three patients had a GRN mutation, two 
subjects had a MAPT mutation and two other patients had a 
mutation in either TBK1 or VCP. A summary of neuropatho-
logically confirmed cases and related genetics in the FTD 
group can be found in Fig. 1. This study was approved by 
the Medical Ethical Committee of the Middelheim General 
Hospital (Antwerp, Belgium, file numbers 2805 and 2806), 
and was conducted in line with the Helsinki Declaration.
Sampling Of Cerebrospinal Fluid And Serum
Lumbar puncture was performed at the L3/L4 or L4/L5 
intervertebral space to collect a total volume of 16.5 mL, 
which was divided across five fractions of 4.5 mL, 1.5 mL, 
1.5 mL, 4.5 mL and 4.5 mL, respectively, in polypropyl-
ene vials (Nalgene; VWR, Leuven, Belgium) [31]. Serum 
was obtained after total blood sampling into two serum gel 
Fig. 1  Overview of neuropathological diagnoses in the FTD group. 
C9ORF72 chromosome 9 open reading frame 72, FTLD-U fronto-
temporal lobar degeneration with ubiquitin-positive inclusions, FTD 
frontotemporal dementia, GRN progranulin gene, TBK1 TANK-bind-
ing kinase 1, TDP-43 transactive response DNA-binding protein of 
43 kDa, VCP valosin-containing protein
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tubes with clotting activator (S-Monovette 7.5 mL Z-gel 
(Sarstedt, Nümbrecht, Germany)), which were centrifuged 
during 10 min at 3000 rpm. Afterwards, serum was distrib-
uted to polypropylene vials. Both CSF and serum samples 
were frozen and stored at – 80 °C until analysis.
RP‑UHPLC‑ECD
An optimized and validated reversed-phase ultra-high-
performance liquid chromatography (RP-UHPLC) system 
with electrochemical detection (ECD) was used to determine 
(nor)adrenaline and its metabolite 3-methoxy-4-hydroxy-
phenylglycol (MHPG), dopamine (DA) and its metabolites 
3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic 
acid (HVA), as well as 5-HT and its metabolite 5-hydroxyin-
doleacetic acid (5-HIAA). The sample preparation consisted 
of a purification on Amicon® Ultra 0.5 Centrifugal Filters 
(cutoff 3000 Da; Millipore, Ireland), which were washed 
twice beforehand with 450 µL buffer while centrifuging 
(14,000×g, 25 min, 4 °C). Serum and CSF were brought 
onto these columns, followed by centrifugation at 4 °C for 
40 min at 14,000×g. The resulting CSF filtrate was diluted 
1:2, and either 1:7 or 1:10, while the filtered serum was 
diluted 1:5 and 1:25 or 1:30. This RP-UHPLC system oper-
ated at an isocratic flow rate of 75 μL/min. The Decade II 
electrochemical detector was equipped with a thin layered 
electrochemical VT03 flow cell fitted with a glassy carbon 
0.7 mm working electrode and an in situ Ag/AgCl (ISAAC) 
reference electrode. Samples of 5 μL were loaded with an 
Alexys AS 110 Autosampler. Separation was achieved using 
a short 15 cm Acquity Column (BEH C18, 1 mm diameter, 
particle size 1.7 μm; Waters, Etten-Leur, the Netherlands) 
[32].
LC–MS/MS
Concentrations of TRP, l-kynurenine (KYN), 3-hydrox-
ykynurenine (HK), anthranilic acid (AA), kynurenic acid, 
xanthurenic acid (XA), quinolinic acid, picolinic acid, and 
nicotinic acid, were determined at the department of Labora-
tory Medicine of the University Medical Center Groningen 
by liquid chromatography in combination with isotope dilu-
tion tandem mass spectrometry (LC–MS/MS) essentially as 
described by [33]. In short, 100 µL of CSF or 50 µL of serum 
was mixed with deuterated or 13C-labeled internal standards 
of the KP compounds under investigation. These mixtures 
were extracted with Strata X-A 96-well plates with a pore 
size of 33 µm and sorbent mass of 30 mg/well (Cat. No.: 
8E-S123-TGB; Strata-X, Phenomenex, Utrecht, the Nether-
lands) and eluted with 3 M HCl in 1-butanol. Finally, 1 µL 
was injected into an Acquity UHPLC (Waters, Etten-Leur, 
the Netherlands) equipped with a Phenomenex Luna col-
umn (Omega C18, 100 × 2.1 mm, particle size 1.6 µm), and 
coupled to a XEVO TQ-S MS/MS system (Waters, Etten-
Leur, the Netherlands). KYN/TRP ratios were calculated 
as a measure for TDO and IDO activity [34] and HK/XA 
ratios as a measure for vitamin B6 function since the enzyme 
converting HK to XA, kynurenine aminotransferase II, is 
pyridoxal phosphate-dependent [35].
Statistics
One-way ANOVA was applied for continuous demographic 
parameters such as age and storage time. In case the assump-
tion of homogeneity of variances was violated, Welch’s 
ANOVA was applied. Fisher’s Exact tests were applied to 
investigate the association between categorical variables 
such as disease category, gender and medication use.
Nonparametric statistics were applied to test inter-group 
differences of monoamines and kynurenines due to the non-
normal distribution of these parameters in CSF and serum. 
Kruskal–Wallis analyses were applied as omnibus tests, 
while post-hoc analyses were performed with Mann–Whit-
ney U statistics. Correction for multiple testing was applied 
using the Benjamini–Hochberg procedure. The results for 
the FTD-ALS group are presented solely as median concen-
trations, as the size of this group was very small and often 
even reduced to n = 2 or n = 3. Therefore, we opted not to 
include monoaminergic and kynurenergic concentrations of 
this group in statistical tests for group comparisons. Lastly, 
Spearman’s rank correlation analysis was used to assess the 
relationship between storage time and concentrations of 
monoamines and kynurenines. Again, Benjamini–Hochberg 
corrections were applied to account for multiple testing. All 
statistical analyses were performed using SPSS version 25.0 
for Windows. Figures were created with GraphPad Prism 
version 6 for Windows (GraphPad Software, La Jolla Cali-
fornia USA, www.graph pad.com).
Results
Demographics
Table 1 summarizes the demographic details of the study 
population. Additional information about the types of medi-
cation across the different disease groups can be found in 
Online Resource 1.
Monoamines
Alterations in the dopaminergic system across disease 
groups were noted in both CSF (H(2) = 9.017, P < 0.05 for 
DOPAC; H(2) = 17.963, P < 0.001 for DA; H(2) = 12.392, 
P < 0.05 for DOPAC/DA and H(2) = 7.252, P < 0.05 for 
HVA/DA) and serum (H(2) = 12.116, P < 0.05 for DOPAC, 
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H(2) = 16.850, P < 0.001 for DA; and H(2) = 19.438, 
P < 0.0001 for DOPAC/DA). A general decrease in DOPAC 
values was observed in FTD and ALS subjects compared 
to the CONTR group. Increased DA concentrations in CSF 
were found in the FTD versus the CONTR and ALS groups. 
In serum, DA levels were also highly significantly increased 
in the FTD subjects compared to CONTR individuals, 
while a similar result was observed between the CONTR 
and ALS group. Analysis of the DOPAC/DA ratio revealed 
a disturbed dopaminergic catabolism in FTD versus the 
CONTR group, evidenced by significantly lower CSF and 
serum DOPAC/DA ratios in the former category. Further-
more, serum DOPAC/DA ratios were severely decreased in 
ALS subjects compared to healthy CONTR subjects (Fig. 2). 
Another index of DA catabolism, CSF HVA/DA, was also 
significantly decreased in FTD compared to CONTR sub-
jects (Fig. 3).
Finally, CSF MHPG differed across diagnostic categories 
(H(2) = 8.833, P < 0.05), with significant differences after 
post-hoc correction indicating higher MHPG levels in FTD 
and ALS compared to the CONTR group (Fig. 4). All results 
of post-hoc comparisons are depicted in Online Resource 2.
Kynurenines
No statistically significant differences were found after 
Kruskal–Wallis analysis for individual compounds belong-
ing to the KP, except for CSF TRP (H(2) = 6.088, P < 0.05), 
however, intergroup comparisons for CSF TRP with post-
hoc Mann–Whitney U tests did not remain significant 
following Benjamini–Hochberg corrections for multiple 
comparisons (Fig. 5). We also found a difference in serum 
HK/XA ratios across diagnostic categories (H(2) = 8.548, 
P < 0.05), with lower serum HK/XA ratios in the ALS versus 
the FTD group (Fig. 6). Post-hoc statistics, in addition to 
median values for HK/XA in each group, are summarized 
in Online Resource 2.
Table 1  Demographics of the study populations for analysis of monoamines and kynurenines
Data regarding age at sampling and sampling time are represented as mean ± standard deviation. For the numbers of subjects taking/not taking 
medication, psychotropic substances, riluzole and dietary vitamin B supplements were taken into account
ALS amyotrophic lateral sclerosis, CONTR control, CSF cerebrospinal fluid, FE Fisher’s Exact, FTD frontotemporal dementia, FTD-ALS fronto-
temporal dementia—amyotrophic lateral sclerosis
Parameter Compounds of interest Sample type CONTR FTD FTD-ALS ALS Test statistic








































Male/female Monoamines CSF 14/12 20/19 1/3 21/2 FE = 14.2; P < 0.05
Serum 14/12 20/19 1/2 18/2 FE = 10.9; P < 0.05
Kynurenines CSF 14/11 20/19 1/3 20/2 FE = 13.1; P < 0.05
Serum 14/12 20/19 1/2 18/2 FE = 10.9; P < 0.05
Taking/not taking medi-
cation
Monoamines CSF 9/7 27/7 0/1 11/6 FE = 5.2
P > 0.05
Serum 10/6 27/7 0/1 11/5 FE = 4.1
P > 0.05
Kynurenines CSF 9/7 27/7 0/1 11/6 FE = 5.2
P > 0.05
Serum 9/7 27/7 0/1 11/5 FE = 5.1
P > 0.05










































Fig. 2  Dopaminergic findings across diagnostic categories. Data are 
represented as box- and whisker plots with minimum–maximum 
ranges. Statistically significant differences after Mann–Whitney U 
tests with Benjamini–Hochberg post-hoc corrections are depicted 
by one, two or three asterisks if P ≤ 0.05, 0.001, or 0.0001, respec-
tively. Sample sizes for CSF DOPAC are: CONTR: n = 26, FTD: 
n = 39, FTD-ALS: n = 4, ALS: n = 23, sample sizes for CSF DA and 
DOPAC/DA are CONTR: n = 21, FTD: n = 35, FTD-ALS: n = 2, 
ALS: n = 17. Sample sizes for serum DOPAC are: CONTR: n = 26, 
FTD: n = 39, FTD-ALS: n = 3, ALS: n = 20, sample sizes for serum 
DA and DOPAC/DA are: CONTR: n = 26, FTD: n = 35, FTD-ALS: 
n = 3, ALS: n = 20. The FTD-ALS group was not included in the sta-
tistical analysis. ALS amyotrophic lateral sclerosis, CONTR control, 
CSF cerebrospinal fluid, DA dopamine, DOPAC 3,4-dihydroxypheny-
lacetic acid, FTD frontotemporal dementia, FTD-ALS frontotemporal 
dementia—amyotrophic lateral sclerosis
Fig. 3  CSF HVA/DA ratios across diagnostic categories. Data are 
represented as box- and whisker plots with minimum–maximum 
ranges. Statistically significant differences after Mann–Whitney U 
analyses with Benjamini–Hochberg corrections are indicated by an 
asterisk (P < 0.05). Sample sizes for CSF HVA/DA are: CONTR: 
n = 21, FTD: n = 35, FTD-ALS: n = 2, ALS: n = 17. The FTD-ALS 
group was not included in the statistical analysis. ALS amyotrophic 
lateral sclerosis, CONTR control, CSF cerebrospinal fluid, DA dopa-
mine, FTD frontotemporal dementia, FTD-ALS frontotemporal 
dementia-amyotrophic lateral sclerosis, HVA homovanillic acid
Fig. 4  CSF MHPG levels across diagnostic categories. Data are rep-
resented as box- and whisker plots with minimum–maximum ranges. 
Statistically significant differences after Mann–Whitney U analy-
ses with Benjamini–Hochberg corrections are indicated by an aster-
isk (P < 0.05). Sample sizes for CSF MHPG are: CONTR: n = 26, 
FTD = 39, FTD-ALS: n = 4, ALS: n = 23. The FTD-ALS group was 
not included in the statistical analysis. ALS amyotrophic lateral scle-
rosis, CONTR control, CSF cerebrospinal fluid, FTD frontotemporal 




Fig. 5  The KP in CSF. Data are represented as box- and whisker plots 
with minimum–maximum ranges. Statistically significant differences 
after Mann–Whitney U analyses with Benjamini–Hochberg correc-
tions are indicated by an asterisk (P < 0.05). Sample sizes for TRP 
are: CONTR: n = 23, FTD: n = 37, FTD-ALS: n = 4, ALS: n = 20, 
sample sizes for KYN are: CONTR: n = 21, FTD: n = 37, FTD-ALS: 
n = 4, ALS: n = 21, sample sizes for HK are: CONTR: n = 24, FTD: 
n = 36, FTD-ALS: n = 4, ALS: n = 21, sample sizes for KA are: 
CONTR: n = 25, FTD: n = 39, FTD-ALS: n = 4, ALS: n = 22, sam-
ple sizes for AA are: CONTR: n = 24, FTD: n = 39, FTD-ALS: n = 4, 
ALS: n = 22, sample sizes for XA are: CONTR: n = 17, FTD: n = 30, 
FTD-ALS: n = 3, ALS: n = 18, sample sizes for QA are: CONTR: 
n = 23, FTD: n = 37, FTD-ALS: n = 4, ALS: n = 21, sample sizes for 
PA are: CONTR: n = 24, FTD: n = 39, FTD-ALS: n = 4, ALS: n = 22, 
sample sizes for NA are: CONTR: n = 25, FTD: n = 39, FTD-ALS: 
n = 4, ALS: n = 22, sample sizes for KYN/TRP are: CONTR: n = 21, 
FTD: n = 35, FTD-ALS: n = 4, ALS: n = 20, sample sizes for HK/XA 
are: CONTR: n = 15, FTD: n = 30, FTD-ALS: n = 3, ALS: n = 18. AA 
anthranilic acid; ALS amyotrophic lateral sclerosis, CONTR control, 
CSF cerebrospinal fluid, FTD frontotemporal dementia, FTD-ALS 
frontotemporal dementia-amyotrophic lateral sclerosis, HK 3-hydrox-
ykynurenine, KA kynurenic acid, KP kynurenine pathway, KYN 
l-kynurenine, NA nicotinic acid, PA picolinic acid, QA quinolinic 
acid, TRP l-tryptophan, XA xanthurenic acid
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Fig. 6  The KP in serum. Data are represented as box- and whisker 
plots with minimum–maximum ranges. Statistically significant dif-
ferences after Mann–Whitney U analyses with Benjamini–Hochberg 
corrections are indicated by an asterisk (P < 0.05). Sample sizes for 
TRP are: CONTR: n = 26, FTD: n = 39, FTD-ALS: n = 3, ALS: 
n = 20, sample sizes for KYN are: CONTR: n = 26, FTD: n = 39, 
FTD-ALS: n = 3, ALS: n = 20, sample sizes for HK are: CONTR: 
n = 24, FTD: n = 39, FTD-ALS: n = 3, ALS: n = 19, sample sizes 
for KA are: CONTR: n = 26, FTD: n = 39, FTD-ALS: n = 3, ALS: 
n = 20, sample sizes for AA are: CONTR: n = 26, FTD: n = 38, FTD-
ALS: n = 3, ALS: n = 20, sample sizes for XA are: CONTR: n = 25, 
FTD: n = 39, FTD-ALS: n = 3, ALS: n = 20, sample sizes for QA are: 
CONTR: n = 25, FTD: n = 37, FTD-ALS: n = 3, ALS: n = 18, sam-
ple sizes for PA are: CONTR: n = 25, FTD: n = 39, FTD-ALS: n = 3, 
ALS: n = 20, sample sizes for NA are: CONTR: n = 24, FTD: n = 38, 
FTD-ALS: n = 3, ALS: n = 20, sample sizes for KYN/TRP are: 
CONTR: n = 26, FTD: n = 39, FTD-ALS: n = 3, ALS: n = 19, sample 
sizes for HK/XA are: CONTR: n = 22, FTD: n = 38, FTD-ALS: n = 3, 
ALS: n = 18
 Neurochemical Research
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Influence of Psychotropic Medication and Storage 
Time
When equivalent analyses were performed to detect differ-
ences in monoamine/kynurenine content only in subjects 
who were free of psychotropic medication and who did not 
take riluzole nor supplements containing vitamin B, a trend 
for increased CSF DA levels in FTD and ALS compared to 
CONTR could be observed (H(2) = 5.751, P = 0.056), but 
none of the monoaminergic differences remained statistically 
significant. In contrast, a significant difference was found for 
CSF TRP across groups (H(2) = 6.548, P < 0.05).
We found that CSF MHPG and DA were negatively 
correlated with storage time (rs(89) =  − 0.409, P < 0.0001 
and rs(73) =  − 0.330, P < 0.05), whereas a positive asso-
ciation between storage time and 5-HIAA (rs(89) = 0.286, 
P < 0.05) as well as 5-HIAA/5-HT ratios (rs(87) = 0.346, 
P ≤ 0.001) was noted. In serum, negative correlations were 
noted between DA levels and storage time (rs(82) =  − 0.242, 
P < 0.05)). As for kynurenines, CSF TRP and serum 
HK/XA ratios decreased with increasing storage time 




A general dopaminergic disturbance was noted in FTD and 
ALS compared to CONTR subjects, largely corresponding to 
previous reports. Single photon emission computed tomog-
raphy has shown decreased frontal uptake of a dopamine 
2 receptor (D2) postsynaptic ligand, as well as a relative 
frontal hypoperfusion in FTD versus CONTR and subjects 
with Alzheimer’s disease [36]. Reduced uptake of 11C-2β-
carbomethoxy-3β-(4-fluorophenyl) tropane (11C-CFT), a 
cocaine analogue targeting DA transporters (DAT), in the 
putamen of FTD subjects was also observed in another study 
[37]. In addition, ALS subjects showed decreased striatal 
binding of 123I-N-(3-iodopropen-2-yl)-2β-carbomethoxy-
3β-(4-chlorophenyl)-tropane (123IPT), a cocaine analogue 
binding specifically to DATs [38]. Furthermore, increased 
DA levels and decreased HVA/DA ratios were observed in 
Brodmann area (BA)46 and BA6 of FTD subjects compared 
to CONTR [29]. Taken together, these findings may all indi-
cate disrupted dopaminergic nerve terminals in projection 
areas of the substantia nigra (SN) and ventral tegmental area 
(VTA). Reduced presynaptic uptake of 123IPT and decreased 
binding of 11C-CFT in ALS and FTD, might reflect a dys-
function of dopaminergic nerve terminals, possibly related 
to presynaptic reuptake mechanisms mediated by DAT. This 
might explain our observation of increased CSF DA levels in 
these disease groups. The decreased DOPAC concentrations 
and DOPAC/DA ratios may then be a result of impaired 
DOPAC synthesis due to dopaminergic neuron dysfunction. 
Exploring the observed dopaminergic alterations in brain 
tissue of FTD and ALS subjects is mandatory to assess the 
validity of this hypothesis.
It would also be interesting to compare the dopaminergic 
disturbance in the FTD-ALS continuum with that observed 
in Parkinson’s disease (PD). In a previous study on dopa-
minergic alterations in CSF of synucleinopathy patients 
[39], among which PD, dopaminergic data of the PD group 
were reduced to eliminate influences of dopaminergic medi-
cation, resulting in a PD group (n = 17) in which only PD 
patients with CSF and plasma l-DOPA values ≤ 5 nmol/L 
and 10 nmol/L, were included. We calculated DA ratios and 
DOPAC ratios in CSF for the disease groups included in our 
study versus the control group (CONTR), as well as identical 
ratios for the PD group versus CONTR in the previous report 
[39]. We observed that the ratios of DOPAC in the FTD, 
FTD-ALS and ALS groups versus CONTR were 0.7, 0.5 
and 0.6, respectively, while this ratio was 0.4 if the DOPAC 
concentrations of the PD group were normalized to CONTR. 
For DA, we noted ratios of 1.3 in both FTD as well as FTD-
ALS groups, and 1.0 in ALS compared to CONTR. In the 
study on catecholaminergic alterations in synucleinopathy 
subjects [39], the PD/CONTR ratio for DA was 0.8.
In this respect, it is clear that the extent of the dopa-
minergic disturbance is most evident in PD, with severely 
decreased CSF DOPAC and DA concentrations compared 
to CONTR. This finding of lowered CSF DOPAC and DA 
concentrations in PD are supported by several other studies 
[40, 41], even though the sample sizes of these studies were 
rather small (n = 4 and n = 7, respectively). It is interesting 
to note that we did not find decreased DA concentrations in 
FTD or ALS, possibly reflecting a distinct disease mecha-
nism from PD.
The dopaminergic alterations in serum of FTD and 
ALS versus CONTR subjects resembled those in CSF, 
which is surprising since DA nor DOPAC readily cross 
the blood–brain barrier (BBB) [42, 43]. However, several 
studies have demonstrated impaired BBB integrity in FTD 
and ALS [44, 45], which might account for the similarities 
observed in CSF and serum.
The use of psychotropic medication may have influenced 
our findings since the dopaminergic alterations could not be 
detected between FTD, ALS or CONTR in a medication-free 
subgroup. However, given the low number of observations 
in this analysis (n = 3–9 per group), type II errors cannot be 
ruled out.
The longer storage time in the CONTR group might have 
led to a false positive result regarding the increased MHPG 
and DA levels in FTD compared to the CONTR group. 
Thus, the absolute DA levels in CSF should be considered 
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carefully, while the DOPAC concentrations and the dopa-
minergic turnover in CSF remain unaffected by storage time.
Based on the therapeutic strategies applied in FTD, we 
expected to find serotonergic (dis)similarities, in the ALS-
FTD continuum. However, our results suggest a shared 
dopaminergic disturbance in CSF and serum, except for 
CSF DA levels. This finding may shift the research in these 
neurodegenerative conditions to DA-based approaches.
Kynurenines
In previous studies investigating the KP in ALS, KYN lev-
els, neuroprotective and neurotoxic KP compounds appeared 
to be altered in this condition [23, 26]. It is possible we 
could not reproduce these findings because of differences in 
CSF handling, alternative analytical conditions, or distinct 
demographics. Since the study of Chen et al. included non-
age-matched CONTR and ALS groups (average age of 36 
and 58 years, respectively) and since the KP is involved in 
aging, these results, particularly with respect to CSF KYN 
[46], KYN/TRP ratios as a measure for IDO-activity, and 
concentrations of QA [47] could also be explained by the 
higher average age in the ALS group.
The results of subjects who did not take psychotropic 
medication, riluzole or vitamin B supplements did indicate 
altered CSF TRP levels between FTD, ALS and CONTR. It 
is difficult to speculate about the (patho)physiological mean-
ing of this result, as lowered KYN/TRP ratios would indicate 
a downregulation of IDO/TDO activity, but no such results 
could be observed. In addition, no serotonergic differences 
were observed in FTD and ALS versus the CONTR group, 
indicating that TRP metabolism was not shifted towards the 
synthesis of serotonergic compounds in these groups. Lastly, 
our observation of decreased serum HK/XA ratios in ALS 
compared to FTD could have been influenced by storage 
time. Another compound of the KP for which we found sig-
nificant differences, CSF TRP, was also influenced by stor-
age time. Based on the results of this study, we suggest that 
the KP offers limited therapeutic value/research potential for 
the FTD-ALS continuum.
Future Perspectives
Although the SN was shown to be affected in FTD and ALS 
[48, 49], the differential pathology in the SN and/or VTA 
of FTD and ALS patients does not represent a well-studied 
topic. It would be interesting to investigate the correlation 
between neuropathological observations in the SN and VTA, 
and dopaminergic disturbance in their projection areas in 
postmortem brain tissue. Alternatively, resting state func-
tional MRI may be applied to assess the functional con-
nectivity between midbrain dopaminergic centers and (pre)
frontal cortical regions, combined with CSF sampling in 
FTD and ALS subjects. Follow-up of these patients may 
then result in a better understanding of dopaminergic distur-
bance, and how this is reflected in bodily fluids. In addition, 
we recommend the analysis of CSF and serum on a clinically 
better characterized population, certainly with respect to the 
ALS group.
In conclusion, we found that ALS and FTD share a dopa-
minergic disturbance in serum, while these changes are also 
partly present in CSF. This could possibly be caused by 
dopaminergic terminal dysfunction in (cortical) projection 
areas of the SN and VTA. The compounds of the KP did not 
appear to be altered in FTD or ALS.
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